FLT3 and acute myeloid leukemia: Among AML patients with nucleophosmin 1 (NPM1) mutation in single center study, those with MRD detected by both multiparameter flow cytometry (FCM) and real-time quantitative polymerase chain reaction (qRT-PCR) were classified as a subgroup with a high relapse risk (46–83%) following chemotherapy [22]; allo-HSCT reduced the CIR and improved DFS in NPM1 + AML in CR1 patients, especially those positive for FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) [23].